GlaxoSmithKline plc Given “Buy” Rating at Galvan Research (GSK)
Other equities research analysts have also recently issued reports about the stock. Analysts at Mainfirst downgraded shares of GlaxoSmithKline plc to an “underperform” rating in a research note on Monday, July 28th. Separately, analysts at Bank of America downgraded shares of GlaxoSmithKline plc from a “buy” rating to a “neutral” rating in a research note on Monday, July 28th. Finally, analysts at Jefferies Group reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Friday, July 25th. Four equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $51.50.
Shares of GlaxoSmithKline plc (NYSE:GSK) traded up 1.04% on Monday, hitting $48.53. 3,994,469 shares of the company’s stock traded hands. GlaxoSmithKline plc has a one year low of $47.51 and a one year high of $56.73. The stock’s 50-day moving average is $52.67 and its 200-day moving average is $53.84. The company has a market cap of $116.6 billion and a price-to-earnings ratio of 14.67.
GlaxoSmithKline plc (NYSE:GSK) last posted its quarterly earnings results on Wednesday, July 23rd. The company reported $0.65 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.71 by $0.06. Analysts expect that GlaxoSmithKline plc will post $3.34 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Thursday, October 2nd. Stockholders of record on Friday, August 8th will be paid a dividend of $0.6482 per share. This represents a $2.59 annualized dividend and a dividend yield of 5.34%. The ex-dividend date is Wednesday, August 6th.
GlaxoSmithKline plc (NYSE:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.